All You Need to Know About Tesamorelin: The Complete Story

3

From laboratory discovery to a $250 million acquisition the science, the struggle, and the business behind the only FDA-approved GHRH peptide

For fifteen years, a small Montreal biotechnology company chased a single molecule through failed trials, regulatory rejections, and a market too small to interest most Big Pharma players. That molecule eventually became Egrifta the only growth hormone-releasing hormone (GHRH) analog ever to earn full FDA approval, and today one of the most talked-about peptides in the wellness and longevity world. This is the full story of tesamorelin: where it came from, how it works, why it exists, who built it, and where the surrounding market stands today.

The Problem That Created the Need

To understand why tesamorelin exists, you have to go back to the mid-1990s and the strange, unintended consequences of one of medicine’s greatest triumphs: the arrival of Highly Active Antiretroviral Therapy (HAART).

Before 1996, an HIV diagnosis was, for most patients, a death sentence measured in a small number of years. Then protease inhibitors arrived, combined into multi-drug regimens, and HIV transformed almost overnight from a terminal illness into a manageable chronic condition. Patients who had been preparing for death were suddenly looking at decades of life.

But the first generation of these life-saving drugs carried a strange and distressing side effect. Patients on long-term antiretroviral therapy particularly those on early protease inhibitors began developing a distinctive pattern of body fat redistribution known as HIV-associated lipodystrophy. Fat would waste away from the face, arms, legs, and buttocks, while simultaneously accumulating in the abdomen, upper back (“buffalo hump”), and around the neck. The abdominal component was the most clinically significant: it wasn’t ordinary subcutaneous fat sitting under the skin, but visceral adipose tissue (VAT) fat packed in and around the internal organs, deep in the abdominal cavity.

Visceral fat is not a cosmetic issue. It is metabolically active tissue that secretes inflammatory cytokines, worsens insulin resistance, drives dyslipidemia (abnormal cholesterol and triglycerides), and is independently associated with cardiovascular risk. For HIV patients who had just been given a second chance at life, this new condition brought its own health burdens and also carried a visible stigma. Lipodystrophy changed how people looked in a way that could inadvertently disclose their HIV status, adding psychological and social distress on top of the physical health risks.

By the late 1990s, there was a clear, well-defined, medically underserved population: people successfully treated for HIV who now had a new, drug-induced metabolic condition with no approved treatment. This was the opening that a small Canadian biotech would spend the next decade and a half trying to fill.

The Underlying Science: Growth Hormone, GHRH, and Why Visceral Fat Responds

To understand the drug, you need a quick primer on the biology it exploits.

The body’s growth hormone (GH) axis is regulated by the hypothalamus, which releases growth hormone-releasing hormone (GHRH) in pulses. GHRH travels a short distance to the anterior pituitary gland, where it binds GHRH receptors and stimulates the synthesis and pulsatile secretion of GH. GH itself acts on many tissues, but a large share of its downstream effects are mediated by insulin-like growth factor 1 (IGF-1), produced mainly in the liver in response to GH signaling.

This pulsatile system is tightly self-regulating. Somatostatin (a separate hypothalamic hormone) suppresses GH release, and elevated IGF-1 feeds back to reduce further GHRH and GH output. The net effect is a system that resists being pushed too far in either direction at least when it is stimulated through its natural upstream signal, GHRH, rather than by dumping exogenous GH directly into the bloodstream.

This distinction matters enormously for a drug developer. Giving a patient synthetic GH directly overrides the feedback loop the pituitary and hypothalamus have no say in the matter, and GH levels can spike unnaturally high, contributing to side effects like edema, joint pain, and insulin resistance. Giving a patient a GHRH analog instead works “one level up” the chain: it still requires the pituitary to do the actual releasing, so the body’s own feedback mechanisms stay intact. In theory (and, over more than a decade of study, largely in practice) this produces a gentler, more physiological elevation in GH and IGF-1.

Why does this matter for visceral fat specifically? Visceral adipocytes are more sensitive to growth hormone’s lipolytic (fat-mobilizing) effects than subcutaneous fat cells are. That biological detail is the reason a GHRH analog can selectively shrink deep abdominal fat while leaving fat elsewhere largely untouched a signature that would later show up clearly and repeatedly in tesamorelin’s clinical trials.

Native human GHRH, however, is a poor drug candidate on its own. It’s a 44-amino-acid peptide, GHRH(1-44), that is rapidly chewed apart in the bloodstream by the enzyme dipeptidyl peptidase-4 (DPP-4) and other proteases. Its natural half-life is measured in minutes. If you wanted to build a marketable, once-daily injectable drug out of GHRH, you needed to solve that stability problem first without losing the molecule’s ability to activate the GHRH receptor.

Discovery: Theratechnologies and the Birth of TH9507

That stability problem was solved by scientists at Theratechnologies, a small Montreal-based biopharmaceutical company, in 1995. According to the company’s own corporate history, Theratechnologies discovered tesamorelin that year and then spent the next fifteen years pursuing its development an unusually long and financially punishing road even by pharmaceutical industry standards.

The scientific breakthrough was elegant rather than complicated. Theratechnologies’ researchers took the full 44-amino-acid GHRH sequence and attached a trans-3-hexenoic acid group (sometimes described as a hexenoyl group) to the N-terminal tyrosine residue at position 1. This single chemical modification made the molecule dramatically more resistant to enzymatic degradation by DPP-4, extending its functional half-life enough to make once-daily subcutaneous dosing feasible, while preserving full agonist activity at the GHRH receptor. In effect, the modification acted like a molecular shield bolted onto the front of the peptide, protecting the vulnerable enzymatic cleavage site without altering the “business end” of the molecule that the receptor actually recognizes.

The resulting compound was given the developmental code name TH9507. It kept the full 44-amino-acid backbone of native GHRH a detail that distinguishes it from many other GHRH-mimetic peptides on the market, several of which are truncated fragments (GHRH 1-29, for instance) rather than the complete sequence. That structural fidelity to the natural hormone, combined with the added stability, is essentially the whole invention.

Interestingly, Theratechnologies wasn’t the only company working in this space in the years that followed. Serono (later part of Merck KGaA) also pursued its own long-acting GHRH analog program during the 2000s, and some scientific literature describes a Serono-associated compound reaching approval and Phase II testing around the same period a reminder that Theratechnologies was operating in a competitive, if narrow, corner of endocrinology research even as it became the company whose molecule ultimately reached the market as an approved drug.

The Long Road Through Clinical Trials

Discovering a stabilized molecule in 1995 was only the beginning. Turning TH9507 into an approved medicine required navigating the entire arc of clinical development: toxicology and early-phase safety studies, dose-finding work, and critically large, randomized, placebo-controlled Phase III trials capable of demonstrating both efficacy and an acceptable safety profile in a population that was itself medically complex (people living with HIV, many on multiple concurrent medications).

The pivotal evidence came from two large, multicenter, double-blind, placebo-controlled Phase III trials enrolling more than 800 patients combined. The lead trial, led by Dr. Julian Falutz of the Montreal General Hospital/McGill University Health Centre in collaboration with Dr. Steven Grinspoon of Massachusetts General Hospital and Harvard Medical School, was published in the New England Journal of Medicine in December 2007 under the title “Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV.” The trial enrolled HIV-infected patients with excess abdominal fat, randomizing them to tesamorelin or placebo for a 26-week main study period, with patients who received tesamorelin then undergoing a second randomization (3:1, tesamorelin to placebo) for a further 26-week extension phase focused on long-term safety.

The results were striking and consistent with the underlying biology. Visceral adipose tissue decreased by 15.2 percent in the tesamorelin group while increasing by 5.0 percent in the placebo group over 26 weeks, alongside meaningful improvements in triglycerides and other lipid measures and, importantly, without the deterioration in glucose control that many researchers had worried might accompany any GH-axis stimulation. A second confirmatory Phase III trial, essentially replicating the design, produced similar results and was later pooled with the first in a combined safety and efficacy analysis published in the Journal of Clinical Endocrinology & Metabolism in 2010, again with Falutz, Grinspoon, and Theratechnologies scientists among the authors.

Subsequent post-hoc and mechanistic analyses, many drawing on the same Phase III datasets, extended the story. Research led by groups including Grinspoon’s team at MGH found that visceral fat reduction with tesamorelin correlated with improvements in liver enzymes and inflammatory markers, hinting at potential relevance to fatty liver disease well beyond the original HIV indication. Later work, including a combined analysis of the Phase III treatment arms, examined the drug’s effect on calculated 10-year cardiovascular risk scores, finding a modest but statistically meaningful reduction driven largely by improvements in total cholesterol.

It’s worth pausing on how unusual the trial design itself was, because it later became a point of controversy. Both pivotal studies mandated that treatment be discontinued at the end of the study period for the safety-extension analysis, meaning that even patients who had responded well had their tesamorelin withdrawn as part of the protocol. Patient advocates and some clinicians later argued this design while scientifically useful for characterizing rebound effects and long-term safety created an ethically awkward situation in which effective treatment was withdrawn from people who were benefiting from it, and that it left real gaps in understanding what happens to patients on truly long-term, uninterrupted therapy. That critique would resurface a few years later on the other side of the Atlantic.

FDA Approval and a Different Answer in Europe

On November 10, 2010, after roughly fifteen years of discovery-to-approval work, the FDA approved tesamorelin under the brand name Egrifta. It became and, as of today, remains the first and only FDA-approved GHRH-analog drug, indicated specifically for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. Notably, the approval also came with a caution that would echo through the drug’s marketing for years afterward: Egrifta is not indicated for weight loss management in patients who are overweight or obese for reasons other than HIV-associated lipodystrophy, and it is not intended as a general growth-hormone replacement or anti-aging therapy. That distinction a specific, narrow indication rather than a broad metabolic or cosmetic one has shaped essentially every regulatory and marketing conversation about the drug ever since.

Buoyed by the U.S. approval, Theratechnologies partnered with the Spanish pharmaceutical company Ferrer Internacional to pursue authorization in Europe, submitting a Marketing Authorisation Application under the name “Tesamorelin Ferrer” in 2011. The European Medicines Agency accepted the filing for review, and Theratechnologies pointed to an estimated 212,000 HIV-infected patients in Europe potentially affected by lipodystrophy as the scale of the opportunity.

It didn’t go the FDA’s way. In June 2012, Ferrer formally withdrew the application after the EMA’s Committee for Medicinal Products for Human Use (CHMP) indicated it could not conclude that the drug had a positive benefit-risk balance based on the data provided. The CHMP had evaluated the documentation and formulated lists of questions, and after assessing the company’s responses, there were still unresolved issues. The committee’s concerns centered on two main points: insufficient long-term safety data beyond roughly 48 weeks, particularly regarding the implications of sustained IGF-1 elevation and the absence of a cardiovascular outcomes endpoint, and perhaps more fundamentally a worry about how the drug would be used in real-world clinical practice, since it would be difficult to differentiate excess abdominal fat caused by lipodystrophy from excess fat simply caused by ordinary obesity. That second concern, in particular, foreshadowed exactly the kind of off-label, indication-creep usage that would in fact emerge over the following decade.

It’s important to be precise about what this withdrawal did and did not mean. It was not a ban and not a rejection based on the drug being unsafe for its approved population it was a voluntary withdrawal by the sponsor in the face of a regulator that wasn’t yet persuaded, and the EMA explicitly noted that withdrawal of an application does not prevent a future resubmission. No such resubmission has succeeded to date, however, and more than a decade later, tesamorelin remains available in the United States but not through centralized EU marketing authorization a genuine and lasting transatlantic divergence in how two major regulators viewed the same clinical dataset.

The People Behind the Trials

Drug approvals are often remembered as corporate or regulatory events, but tesamorelin’s path through the clinic had a consistent cast of clinician-scientists whose names appear again and again across the published record.

Dr. Julian Falutz, an infectious disease physician at the Montreal General Hospital and McGill University Health Centre, served as lead investigator on both pivotal Phase III trials and is the first author on the drug’s foundational 2007 NEJM paper as well as the pooled 2010 analysis in the Journal of Clinical Endocrinology & Metabolism. Falutz had a long-standing research interest in the metabolic complications of HIV therapy, which made him a natural fit to lead a trial testing a novel intervention for exactly that problem. Working alongside him was Dr. Steven Grinspoon, an endocrinologist at Massachusetts General Hospital and Harvard Medical School who has spent much of his career studying HIV-associated metabolic and body-composition abnormalities; Grinspoon and his MGH colleagues, including Dr. Takara Stanley and Dr. Lindsay Fourman, went on to author much of the secondary and mechanistic research exploring tesamorelin’s effects on liver enzymes, inflammatory markers, and cardiovascular risk in the years following approval.

On the company side, Theratechnologies employees including Diane Potvin, Jean-Claude Mamputu, and Christian Marsolais, among others named as co-authors across the trial publications worked alongside these academic investigators to design, run, and analyze the studies, with Quintiles Canada (now part of IQVIA) handling the statistical analysis for the original NEJM trial. The New England Journal of Medicine paper itself is explicit that Theratechnologies both funded and helped design the study in consultation with Falutz and Grinspoon a standard industry-sponsored trial arrangement, but one worth naming plainly, since the company’s employees and equity holders were themselves credited authors on the pivotal efficacy paper. This is neither unusual nor inherently improper in industry-funded drug development, but it’s the kind of detail worth knowing when evaluating any single-sponsor trial program, tesamorelin’s included.

It’s also worth noting how small and specialized this research community was and largely remains. Unlike a common-disease drug program with dozens of competing trial sites and independent research groups, tesamorelin’s evidence base was generated by a fairly compact circle of HIV-metabolism specialists working in close, sustained collaboration with one manufacturer over more than a decade which helps explain both the internal consistency of the findings across multiple papers, and why so much of the mechanistic follow-up research (on liver fat, inflammation, and cardiovascular risk) continued to come from the same two or three institutions long after the original approval.

The Business Behind the Molecule: Theratechnologies’ Long Commercial Journey

Getting a drug approved is only half the battle; building a viable commercial business around it is the other half, and for Theratechnologies this proved almost as difficult as the science.

At launch, Theratechnologies did not commercialize Egrifta directly in the U.S. Instead, EGRIFTA was first marketed in the U.S. by a third-party commercial partner a common strategy for smaller biotechs that lack an established sales infrastructure, but one that also meant Theratechnologies captured only a fraction of the drug’s commercial value in its early years on the market. That arrangement didn’t last. In 2014, Theratechnologies reoriented its business model to become a commercial-stage biopharmaceutical company and regained U.S. commercial rights to Egrifta, taking direct control of sales, marketing, and distribution for the first time.

The company then worked to diversify beyond a single product. In 2016, Theratechnologies concluded an agreement to acquire the commercial rights to Trogarzo (ibalizumab-uiyk) in the U.S. and other markets a monoclonal antibody indicated for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection. This gave the company a second HIV-focused revenue stream and reduced its dependence on Egrifta alone, a strategically important move given how much of Theratechnologies’ history had already been shaped by the fortunes of a single molecule.

Over the following formulation evolved as well. The original Egrifta required daily reconstitution of a lyophilized powder an inconvenient, fiddly process for patients self-injecting every day. In 2017, Theratechnologies launched Egrifta SV, a more concentrated, simpler-to-reconstitute formulation designed to reduce that daily burden and improve adherence. Nearly a decade later, the company pushed the formulation science further still: after working through FDA queries related to immunogenicity and microbiology testing, Theratechnologies developed what it called the “F8 Formulation,” approved and launched in 2025 as Egrifta WR a version enabling weekly rather than daily reconstitution, a meaningful quality-of-life improvement for a chronic daily-injection therapy.

Show Me the Money: Revenue, Market Size, and Financial Reality

For a drug this well-known in wellness circles, it’s worth being honest about the actual commercial scale involved and it is modest by pharmaceutical industry standards. Egrifta has never been a blockbuster in the traditional sense; its approved population (HIV patients specifically with clinically significant lipodystrophy) is a genuinely narrow slice of the overall HIV-treated population, let alone the broader population of people interested in visceral fat reduction.

Theratechnologies’ own reported financials illustrate this clearly. For full-year 2023, the company reported total revenue of $81.8 million. For 2024, Theratechnologies reported revenue of $85.9 million, a 5% increase from the prior year, with EGRIFTA SV sales reaching $60 million for the full year, up 12% from the prior year, while its other drug, Trogarzo sales came in at $25.7 million, down 8% amid competitive pressures. That means the entire global commercial footprint of the only FDA-approved GHRH peptide on Earth, in the year before this article was written, generated on the order of $60 million in net sales a figure that would be considered a rounding error for most large pharmaceutical companies, but represents the core lifeblood of a small specialty biotech.

2025 brought turbulence. The company struggled with a supply disruption for Egrifta due to an issue with a contract manufacturer, and Theratechnologies disclosed that a shortage forced it to temporarily halt distribution of Egrifta SV in late 2024 and early 2025. The FDA authorized the release of two withheld batches on February 13, 2025, and the company resumed distribution to distributors on February 14, 2025, triggering a rush of inventory-rebuilding orders from wholesalers like McKesson and specialty pharmacies that temporarily inflated Q1 2025 sales figures before demand normalized. By Q2 2025, EGRIFTA SV net sales for the six-month period had actually declined 3.0% year-over-year, reflecting both the lingering effects of the supply disruption and new government rebates tied to the Inflation Reduction Act’s Medicare drug pricing provisions.

Despite the volatility, Egrifta remained the company’s primary growth engine relative to Trogarzo, whose sales were increasingly squeezed by newer, competing therapies for multidrug-resistant HIV.

The Future Pak Acquisition: A Company Changes Hands

The single most consequential business event in tesamorelin’s recent history is the sale of Theratechnologies itself.

The pursuit began in 2024, when Future Pak LLC a privately held U.S. contract manufacturer, packager, and distributor of pharmaceutical and nutraceutical products based in Wixom, Michigan made an initial approach to acquire the company. Future Pak’s first attempt to acquire Theratechnologies, an offer of roughly $100 million, was rebuffed in August 2024 as too low. Future Pak didn’t give up. The company returned to the table in January 2025, and after being turned away again because Theratechnologies had already entered an exclusivity arrangement with a different prospective acquirer, Future Pak went public with its interest in April 2025, disclosing that it had submitted two formal proposals since January and that its most recent offer cash consideration of $3.51 to $4.50 per share, implying a total enterprise value of up to $255 million represented a premium of 164% to 238% over Theratechnologies’ closing stock price of $1.33 on April 10, 2025.

That public pressure worked. Theratechnologies opened a formal sale process, soliciting interest from multiple potential counterparties under the oversight of a special committee of independent directors, advised by Barclays Capital as exclusive financial advisor and Raymond James providing an independent fairness opinion. The resulting agreement, announced July 2, 2025, saw CB Biotechnology (an affiliate of Future Pak) agree to acquire Theratechnologies for US$3.01 per share in cash plus a contingent value right (CVR) for additional payments of up to US$1.19 per share, tied to future performance milestones for the Egrifta franchise. The CVR structure specifically ties additional payouts to EGRIFTA gross profit thresholds: if the franchise’s 12-month gross profit surpasses $40 million at the 12-, 24-, or 36-month anniversaries of closing, 50% of the profit above that threshold flows to CVR holders, and a cumulative $150 million gross profit milestone over 36 months triggers an additional one-time $10 million payment with a further $15 million payable if combined EGRIFTA-and-Trogarzo gross profit tops $250 million over that same period. In other words, part of what Theratechnologies shareholders receive depends directly on how well tesamorelin performs commercially over the next three years under its new owner.

The transaction closed with Barclays Capital representing Theratechnologies and Cleary Gottlieb representing Barclays in the deal, and after clearing shareholder and court approval in Quebec, the acquisition officially completed on September 25, 2025, with Theratechnologies’ shares delisted from both the Toronto Stock Exchange and Nasdaq shortly thereafter. Theratechnologies the company that discovered tesamorelin in 1995 and spent fifteen years bringing it to market ceased to exist as an independent, publicly traded entity almost exactly fifteen years after Egrifta’s original FDA approval, now owned by a contract manufacturer rather than a company built around drug discovery.

The Off-Label Explosion: Longevity Medicine, Compounding, and the Gray Market

Here is where the story of tesamorelin diverges sharply from most niche HIV therapeutics: it has become one of the most requested peptides in the wellness, anti-aging, and performance-medicine world a use case that has almost nothing to do with the population in which it was studied and approved.

The appeal is straightforward to understand. Tesamorelin is the only GHRH analog with a fully validated Phase III efficacy and safety dataset, a real FDA approval, and a defined mechanism for shrinking visceral fat specifically the type of fat most closely associated with metabolic disease and, cosmetically, with a thicker midsection. Other popular GHRH-pathway peptides discussed in longevity circles, such as sermorelin (whose original branded version, Geref, was an FDA-approved product before being discontinued in 2008) and the various CJC-1295 formulations, exist entirely as compounded or research-grade products without anything close to tesamorelin’s clinical trial pedigree. For prescribers and patients looking for the most “evidence-backed” option in this peptide family, tesamorelin’s approval status is a significant selling point even though that approval covers a narrow HIV-specific indication and says nothing directly about its use in metabolically healthy adults pursuing body recomposition or anti-aging goals.

This off-label demand has driven a genuinely large secondary market that operates largely outside Theratechnologies’ and now Future Pak’s direct control, running through two channels.

Compounding pharmacies. Under Section 503A of the Federal Food, Drug and Cosmetic Act, licensed pharmacies can compound customized medications for individual patients under physician prescription, generally in circumstances where a commercially available FDA-approved product cannot meet a specific patient’s need. Larger 503B outsourcing facilities can compound at scale under separate FDA oversight. Egrifta’s own periodic supply shortages like the manufacturing disruption that hit in late 2024 and early 2025 have at times created exactly the kind of “commercially unavailable” gap that legally opens the door for broader compounding activity, and compounded tesamorelin has become considerably more accessible to prescribers willing to write off-label scripts for metabolic optimization, body recomposition, or general longevity protocols.

Research-chemical vendors. A parallel, less regulated channel exists online, where companies sell tesamorelin (and dozens of other peptides) explicitly labeled “for research use only, not for human consumption.” These vendors typically provide a Certificate of Analysis documenting HPLC purity testing, but the product is not manufactured under pharmaceutical Good Manufacturing Practice standards, is not dispensed under prescription, and its use for actual human self-administration sits well outside FDA-authorized channels carrying meaningfully greater risk of contamination, mis-dosing, and inconsistent potency compared to either the approved drug or legitimately compounded versions.

This gray-market growth has not gone unnoticed by regulators. In 2026, an FDA advisory committee reviewed the entire category of compounded growth-hormone secretagogues including sermorelin, tesamorelin, and ipamorelin and voted overwhelmingly to recommend tighter restrictions, citing rising adverse-event reports, a lack of long-term safety data, and widespread unapproved marketing for anti-aging and wellness purposes. FDA officials told the panel that adverse-event reports linked to these compounded peptides have climbed sharply in recent years, with patients describing symptoms ranging from joint pain and swelling to elevated blood sugar and, in rarer cases, more serious complications. The committee’s stated goal was to limit large-scale, essentially unsupervised compounding of these peptides while still preserving legitimate access for patients with genuine medical need a balance that regulators, prescribers, and patients will continue negotiating in the years ahead.

The bottom line for anyone considering off-label tesamorelin: it is legal for a licensed physician to prescribe it off-label and for a compliant, licensed pharmacy to dispense a compounded version, but this exists in a genuine regulatory gray zone shaped by supply availability, evolving FDA scrutiny, and the documentation practices of individual prescribers and pharmacies. Products marketed as “research use only” and sold without a prescription for direct self-administration sit outside that legal framework entirely, regardless of how they’re marketed.

What Tesamorelin Actually Does: Dosing, Formulations, and Clinical Effects

Setting the regulatory drama aside, it’s worth returning to what the drug itself actually does and how it’s used in its approved context.

• Mechanism, recap: Tesamorelin stimulates the pituitary to release the body’s own growth hormone in a pulsatile, physiological pattern by activating GHRH receptors, rather than replacing GH directly. This raises circulating IGF-1, the main downstream mediator of GH’s metabolic effects, while in trial populations at least largely preserving normal glucose tolerance and the body’s natural hormonal feedback loops.
• Clinical effects: Across the pivotal Phase III program, visceral adipose tissue fell by roughly 15-18% over 26 weeks of treatment relative to placebo, with subcutaneous fat largely unaffected the selective visceral-fat signature that is tesamorelin’s clinical calling card. Lipid parameters, especially triglycerides and total cholesterol, improved in parallel. Later analyses of the same trial data found associations between visceral fat reduction and improvements in liver enzymes (ALT and AST) and systemic inflammatory markers, and a modest reduction in calculated cardiovascular risk scores interesting secondary findings that have fed some of the interest in exploring tesamorelin for non-alcoholic fatty liver disease, though that remains investigational rather than an approved use.
• Formulations and dosing: The original Egrifta required daily reconstitution of lyophilized powder for subcutaneous self-injection, typically into the abdomen. Egrifta SV, launched in 2017, offered a more concentrated formulation that simplified though didn’t eliminate the daily reconstitution process. Egrifta WR, approved in 2025 using the company’s “F8 Formulation,” extended reconstitution intervals to weekly, a substantial convenience improvement for patients managing a chronic daily-injection regimen.
• Side effects: The most commonly reported adverse effects in trials and clinical use include injection-site reactions (redness, itching, swelling), joint pain and muscle aches (arthralgia and myalgia), and peripheral edema (fluid retention, often noticeable as swelling in the hands or feet) all broadly consistent with what would be expected from elevated GH/IGF-1 signaling. Because IGF-1 plays a role in cell proliferation, the drug is generally avoided in patients with active malignancy, and long-term monitoring of IGF-1 levels is part of standard clinical management.

Where Tesamorelin Sits in the Broader Peptide Landscape

Tesamorelin occupies a genuinely unique position among growth-hormone secretagogue peptides: it is the only member of its class with a completed, FDA-reviewed Phase III program and a standing drug approval. Sermorelin, often discussed alongside it, was itself briefly FDA-approved decades ago (as Geref, for diagnostic and pediatric growth-hormone-deficiency use) before that branded product was discontinued in 2008; sermorelin today exists almost entirely as a compounded product without an active adult indication. CJC-1295 and ipamorelin, two other frequently discussed compounds in the same broad category, have never carried FDA approval for any human indication and exist purely in the compounded and research-chemical space.

That distinction matters both scientifically and practically. It means tesamorelin has, by a wide margin, the most robust published human safety and efficacy dataset of any peptide in this class but it also means the entire foundation of that dataset comes from HIV-positive patients with a specific, clinically defined condition, not from the metabolically healthy, non-HIV population increasingly seeking it out for body composition and longevity purposes. The gap between “this is the best-studied peptide in its category” and “this is well-studied for the use case I actually want it for” is one worth sitting with honestly, whether you’re a patient, a prescriber, or simply someone trying to make sense of the peptide landscape.

Looking Ahead

Tesamorelin’s story is still being written on two very different tracks. On the approved-medicine track, Egrifta WR represents the latest iteration of a molecule now sixteen years into commercial life, under new ownership focused on maximizing an established, if modest, revenue franchise the CVR structure in the Future Pak deal essentially bets real money on the drug’s continued commercial performance over the next three years. On the off-label track, tesamorelin sits at the center of a much larger and faster-moving conversation about compounded peptides, longevity medicine, and how regulators should balance patient access against the risks of unsupervised, large-scale compounding of drugs that were never studied in the populations now using them.

Whichever track you’re most interested in, the underlying facts are worth holding onto: this is a peptide discovered in a Montreal lab in 1995, carried through fifteen years and two pivotal Phase III trials by a small team of Canadian and American researchers and clinicians, approved by the FDA in a narrow HIV-specific indication in 2010, rejected on a technicality of unresolved evidence in Europe in 2012, expanded through three successive formulations, and ultimately sold along with its parent company for roughly a quarter of a billion dollars in 2025 even as its real-world use has quietly outgrown the label it was built for.

Key Pioneers Behind Tesamorelin

Dr. Andrew V. Schally, Ph.D. (Foundational GHRH Discoverer)

• Role: Nobel Laureate in Physiology or Medicine (1977).
• Institution: Veterans Affairs Medical Center / University of Miami.
• Contribution: Dr. Schally isolated, characterized, and synthesized the natural 44-amino-acid structure of human Growth Hormone-Releasing Hormone (GHRH) from human hypothalamus tissue. Tesamorelin is built directly upon his original GHRH 1-44 sequence.

Dr. Roger Guillemin, M.D., Ph.D. & Dr. Paul Brazeau, Ph.D. (Co-Discoverers of GRF/GHRH)

• Role: Neuroendocrinologists and Salk Institute Researchers.
• Institution: Salk Institute for Biological Studies / Université de Montréal.
• Contribution: Co-discovered natural Growth Hormone-Releasing Factor (GRF/GHRH) in 1982. Dr. Brazeau later collaborated with Theratechnologies Inc. in Montreal to study synthetic GHRH analogs, providing early pharmacological evaluations that led to TH9507 (Tesamorelin).

Dr. Thierry Abribat, Ph.D. & Dr. Michel Ibea, Ph.D. (Patenting Scientists & Chemical Designers)

• Role: R&D Lead Scientists and Patent Co-Inventors at Theratechnologies Inc.
• Institution: Theratechnologies Inc. (Montreal, Canada).
• Contribution: Engineered the specific chemical structure of Tesamorelin by attaching a trans-3-hexenoic acid group to the N-terminus of human GHRH. This modification protected the peptide from rapid enzymatic breakdown (specifically by the DPP-4 enzyme), giving it the extended stability and half-life required for practical daily human administration.

Dr. Steven Grinspoon, M.D. (Pivotal Clinical Trial Lead)

• Role: Lead Senior Principal Investigator for Phase III Clinical Trials.
• Institution: Harvard Medical School / Massachusetts General Hospital.
• Contribution: Primary clinical architect behind evaluating GHRH analogues for metabolic and visceral fat disorders. He designed and published the landmark Phase III clinical trials in The New England Journal of Medicine (NEJM), demonstrating that Tesamorelin selectively reduces visceral abdominal fat while maintaining beneficial subcutaneous fat.

Dr. Julian Falutz, M.D. (Primary Clinical Researcher)

• Role: Co-Principal Investigator and Lead Author for Phase II & III Clinical Trials.
• Institution: McGill University Health Centre (Montreal, Canada).
• Contribution: Headed the clinical safety and efficacy evaluation of Tesamorelin (TH9507). His multi-center clinical trial datasets served as the primary clinical evidence submitted to regulatory authorities, directly enabling FDA approval in 2010.

Dr. Janet Lo, M.D., M.M.Sc. (Cardiovascular & Metabolic Researcher)

• Role: Associate Director and Senior Clinical Researcher.
• Institution: Massachusetts General Hospital / Harvard Medical School.
• Contribution: Spearheaded clinical evaluations analyzing secondary cardiovascular and liver benefits of Tesamorelin, showing its ability to lower liver fat (hepatic steatosis) and reduce carotid intima-media thickness in patients with metabolic syndrome.

Overview of Theratechnologies Inc. : The Makers of Tesamorelin

Company Overview

Theratechnologies Inc. is a specialty biopharmaceutical company headquartered in Montreal, Quebec, Canada. Founded in 1993, the enterprise transitioned over three decades from a pure-play research laboratory into an integrated, commercial-stage biopharmaceutical organization. The foundation of the company’s scientific identity rests upon peptide design and targeted metabolic interventions.

In 1995, internal researchers at Theratechnologies synthesized TH9507, a stabilized synthetic analogue of human Growth Hormone-Releasing Hormone (GHRH) featuring a custom trans-3-hexenoic acid tail. This specific chemical modification prevented rapid enzymatic breakdown in human plasma, providing the pharmacological stability needed for once-daily administration. Over the subsequent 15 years, the company guided TH9507 through pre-clinical characterization and Phase I through Phase III clinical evaluation.

These efforts culminated in late 2010 when the U.S. Food and Drug Administration (FDA) granted marketing approval for the molecule under the international non-proprietary name tesamorelin and the trade name EGRIFTA® to treat excess visceral abdominal fat in HIV-infected patients suffering from lipodystrophy.

Historically, commercialization of breakthrough molecules was delegated to large pharma distribution partners (such as EMD Serono in the United States). However, in 2014, Theratechnologies executed a fundamental strategic pivot. The leadership team reclaimed full commercialization rights for tesamorelin in major markets, transitioning the firm into a vertically integrated commercial entity.

Today, the company manages its own specialized medical affairs, clinical development, regulatory, and direct sales infrastructure across North America and select European territories.

Beyond its commercial core in endocrinology and metabolic disorders, Theratechnologies maintains research programs centered on oncology and liver diseases. Utilizing proprietary peptide-drug conjugate (PDC) technology platforms, the company seeks to leverage short peptides to deliver cytotoxic agents directly to receptors overexpressed on cancer cells (such as SORT1/Sortilin), aiming to maximize tumor destruction while minimizing off-target toxicity.

Company Type

• Entity Classification: Publicly traded biopharmaceutical company (Commercial-Stage).
• Stock Exchange Listings: Dual-listed on the NASDAQ Stock Market under the ticker symbol THTX and on the Toronto Stock Exchange (TSX) under the ticker symbol TH.

Valuation & Financial Metrics

• Market Capitalization: Approximately $155.88 Million USD.
• Annual Revenue (TTM): ~$84.37 Million USD.
• Financial Profile: Supported by consistent product revenue generated by its commercialized HIV franchise (EGRIFTA SV® and Trogarzo®), which funds late-stage clinical research, formulation advancements (such as once-weekly or pen-injector tesamorelin variants), and pipeline platform expansions.

Target Market & Therapeutic Focus

Theratechnologies concentrates its commercial and clinical efforts on specialized, high-unmet-need therapeutic areas:

1. Metabolic Health & Endocrinology: Primary focus on visceral adiposity, lipodystrophy, and metabolic complications in specialized patient populations.
2. Specialized Virology (HIV Care): Providing targeted therapies for adults living with HIV who experience metabolic side effects (visceral fat accumulation) or multidrug-resistant (MDR) viral loads.
3. Hepatology & Liver Disease: Investigating GHRH receptor modulation to treat metabolic dysfunction-associated steatohepatitis (MASH) and non-alcoholic fatty liver disease (NAFLD).
4. Targeted Oncology: Developing peptide-drug conjugates (PDCs) targeting sortilin-expressing solid tumors (such as triple-negative breast cancer and ovarian cancer).

Other Commercial Products & Clinical Pipeline

Theratechnologies’ commercial portfolio and development pipeline include:

• EGRIFTA SV® (tesamorelin for injection): The updated, concentrated small-volume formulation of tesamorelin approved by the FDA in 2019. It requires a significantly smaller injection volume, does not require reconstitution refrigeration prior to mixing, and offers improved patient convenience compared to the original 2010 formulation.
• Trogarzo® (ibalizumab-uiyk injection): A long-acting CD4-directed post-attachment HIV-1 inhibitor monoclonal antibody. Approved by the FDA in 2018 for heavily treatment-experienced adults with multidrug-resistant HIV-1 failing their current antiretroviral regimen. It blocks viral entry into host cells while preserving normal immune system function.
• TH1902 (Investigational PDC): A novel peptide-drug conjugate combining a proprietary peptide ligand with docetaxel, designed to target the Sortilin (SORT1) receptor for the treatment of SORT1-positive solid tumors (e.g., triple-negative breast cancer).
• EGRIFTA WR™ / F8 Formulation (Investigational): Advanced, reconstituted-stable or multi-dose formulations of tesamorelin aimed at easing the daily administration burden for chronic users.

Executive Leadership Team

Note on Organizational Structure: Theratechnologies operates with a lean executive structure common to specialized biotech firms. Executive authority flows directly from the Chief Executive Officer to functional Senior Vice Presidents leading Finance, Medical/Scientific Affairs, and Commercial Operations. Operations are directly integrated under executive oversight rather than managed by a separate COO.

Chief Executive Officer (CEO)

• Executive: Paul Levesque
• Role & Background: President, Chief Executive Officer, and Member of the Board of Directors. Joined Theratechnologies in 2020 following a long tenure at Pfizer, where he served as Global President of Pfizer Rare Diseases. He holds deep international experience in commercial strategy, orphan drug development, and global pharmaceutical launches.

Chief Financial Officer (CFO)

• Executive: Philippe Dubuc
• Role & Background: Senior Vice President and Chief Financial Officer. Appointed in 2016, Dubuc oversees capital allocation, investor relations, corporate finance, and treasury. Prior to joining Theratechnologies, he spent years in healthcare investment banking, serving as Managing Director of Investment Banking at National Bank Financial.

Chief Medical Officer (CMO)

• Executive: Christian Marsolais, Ph.D.
• Role & Background: Senior Vice President and Chief Medical Officer. Dr. Marsolais oversees all global clinical development, medical affairs, regulatory filings, and pharmacovigilance operations. Prior to joining Theratechnologies, he held senior medical affairs and clinical research positions at Pfizer Global Pharmaceuticals, Sandoz Canada, and BioChem Therapeutics.

Chief Technology Officer (CTO) / Head of R&D Operations

• Executive Oversight: Biochem & Technical Operations Steering Group
• Role & Background: Early peptide synthesis technology and chemical development were directed by founding scientists, including Dr. Thierry Abribat and Dr. Michel Ibea (co-inventors on the original tesamorelin patents). Modern pharmaceutical manufacturing, quality control, technical ops, and supply-chain logistics for complex peptides are managed under the Senior Vice President of Technical Operations and Global Supply Chain.

Chief Operating Officer (COO)

• Executive Oversight: Directly integrated into Executive Leadership
• Role & Background: Theratechnologies does not utilize a standalone COO title. Operational execution, commercial logistics, and corporate administration are shared directly among CEO Paul Levesque, CFO Philippe Dubuc, and functional Vice Presidents across North American and European operational hubs.

FAQ’s About Tesamorelin

What is Tesamorelin and how does it work?

Tesamorelin is a synthetic Growth Hormone-Releasing Hormone (GHRH) analogue. It works by binding to GHRH receptors in the pituitary gland, stimulating the natural production and release of endogenous Growth Hormone (GH), which subsequently elevates IGF-1 levels to target visceral fat.

Is Tesamorelin FDA-approved?

Yes. It was FDA-approved in 2010 (brand name Egrifta / Egrifta SV) specifically to reduce excess abdominal (visceral) fat in HIV-infected patients with lipodystrophy.

What is the difference between Tesamorelin and standard HGH?

Standard Human Growth Hormone (HGH) introduces synthetic, exogenous hormone directly into the body, which can shut down natural GH production via negative feedback. Tesamorelin stimulates your body to make its own GH in a natural, pulsed manner, keeping the feedback loop intact.

How is Tesamorelin different from Sermorelin or CJC-1295?

All three are GHRH analogues, but Tesamorelin is uniquely structured with a hexenoyl moiety (an attached fatty acid chain). This modification gives it a longer half-life, improved stability, and specific clinical backing for visceral fat reduction compared to Sermorelin or CJC-1295.

Will Tesamorelin make me lose overall body weight?

Not necessarily. Tesamorelin specifically targets deep visceral adipose tissue (VAT) the dangerous fat surrounding abdominal organs, rather than subcutaneous fat (the soft fat under the skin). Because it may increase lean muscle mass, scale weight might stay the same even as belly size shrinks.

How long does it take to see results from Tesamorelin?

Clinical trials show significant reductions in visceral belly fat after 13 to 26 weeks of consistent daily administration, though subtle changes in muscle recovery and energy can occur sooner.

Will the visceral fat return if I stop taking Tesamorelin?

Yes. Clinical studies indicate that if treatment is discontinued, visceral fat tends to gradually return to baseline levels over several months without sustained lifestyle adjustments.

Does Tesamorelin build muscle?

While its primary FDA-approved indication is fat loss, the resulting rise in Growth Hormone and IGF-1 can support muscle preservation, improved protein synthesis, and enhanced recovery from exercise.

How is Tesamorelin administered?

It is administered via a daily subcutaneous (under the skin) injection directly into the abdominal area below the navel.

When is the best time of day to inject Tesamorelin?

It is typically injected once daily at around the same time, often on an empty stomach (either first thing in the morning or before bed) to avoid interference from elevated blood sugar and insulin levels.

Do I need to rotate injection sites?

Yes. You should rotate injection spots on your lower abdomen to avoid tissue irritation, bruising, or the formation of hard bumps (lipohypertrophy). Never inject into scar tissue, bruises, or directly into the belly button.

How should Tesamorelin be stored?

Unreconstituted (powder) vials should be kept refrigerated or at cool room temperatures away from light, depending on the manufacturer’s directions. Once reconstituted with sterile or bacteriostatic water, it must be refrigerated and used within a specified timeframe.

What are the most common side effects of Tesamorelin?

Common side effects include mild injection site reactions (redness, itching, swelling), temporary joint stiffness (arthralgia), muscle aches, fluid retention/mild swelling in hands or feet, and mild tingling/numbness.

Does Tesamorelin raise blood sugar levels?

Yes, it can. Growth Hormone naturally opposes insulin action, which can increase blood glucose levels or cause insulin resistance. Fasting glucose and HbA1c should be monitored, especially in prediabetic or diabetic patients.

Can Tesamorelin cause carpal tunnel syndrome?

It can happen occasionally. Water retention caused by elevated growth hormone levels can compress the median nerve in the wrist, leading to wrist pain or hand numbness.

Is Tesamorelin safe for people with a history of cancer?

No. Because Tesamorelin increases IGF-1 (a growth factor that encourages cell proliferation), it is strictly contraindicated in individuals with active cancer or a history of pituitary tumors.

Can non-HIV patients use Tesamorelin off-label for general weight loss?

While physicians sometimes prescribe it off-label to non-HIV patients dealing with high visceral fat or low GH, it is not FDA-approved as a general anti-obesity drug. GLP-1 agonists (like Tirzepatide or Semaglutide) are far more effective for broad weight loss.

Can women take Tesamorelin?

Yes, unless pregnant or breastfeeding. Tesamorelin carries a strict FDA warning against use during pregnancy because modifying body fat balance during pregnancy can cause fetal harm.

What lab tests should be monitored while taking Tesamorelin?

Doctors regularly monitor:

• IGF-1 levels (to ensure GH stimulation isn’t excessive)
• Fasting Blood Glucose / HbA1c (to check for onset of diabetes)
• Liver & Kidney panel

Does Tesamorelin suppress natural testosterone production?

No. Tesamorelin acts on the pituitary-GH axis, not the hypothalamic-pituitary-gonadal (HPG) axis. It does not shut down natural testosterone or luteinizing hormone (LH) output.